News | April 07, 2008

CAD Risk Less, Endothelial Function Improved in Cleaner Environment

April 8, 2008 - A study using Itamar Medical's Endo-PAT2000, an FDA-cleared device used to assess endothelial function, found that when indoor air particles are reduced in a controlled study environment, endothelial function, an indicator of cardiovascular health, significantly improves.

Itamar Medical's Endo-PAT2000 was used for evaluating the effect of high-efficiency particulate air (HEPA) filters on endothelial function in healthy elderly patients residing close to major roads. Vaclavik et al. found that air filtration significantly improved endothelial function in the study subjects (Vaclavik et al. Indoor Particles Affect Vascular Function in the Aged. American Journal of Respiratory and Critical Care Medicine 2008; Vol 177. pp. 419-425). Endothelial function is an important indicator of vascular health, so much so that endothelial dysfunction has been described as the "ultimate risk of risk factors" (Bonetti et al., Endothelial Dysfunction: A Marker of Atherosclerotic Risk, ATVB, 2003;23;168-175).

Both short-term and long-term exposure to ambient levels of particulate are associated with increased fatalities related to respiratory and cardiovascular disease. Researchers in the study believe endothelial dysfunction, which is a strong predictor of adverse cardiovascular conditions, may be the source of this increase in respiratory and cardiovascular diseases.

For more information: www.itamar-medical.com

Related Content

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting| January 17, 2018 | Dave Fornell
There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or b
Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting| December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
The Xience Sierra stent.
Technology | Stents Drug Eluting| November 09, 2017
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience
Synergy Stent With Shorter DAPT Superior to Bare-Metal Stent in Elderly Patients
News | Stents Drug Eluting| November 06, 2017
November 6, 2017 — Elderly patients undergoing...
Biotronik Orsiro DES Shows Low Five-Year Event Rates
News | Stents Drug Eluting| November 03, 2017
November 3, 2017 — Biotronik's Orsiro...
Three-Month DAPT Non-Inferior for ACS Patients Treated With Combo Dual Therapy Stent

Image courtesy of OrbusNeich

News | Stents Drug Eluting| November 01, 2017
OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at the 29th annual...
News | Stents Drug Eluting| October 25, 2017
Elixir Medical Corp. announced it will unveil a new metallic drug-eluting stent (DES) platform at this year’s...
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting| September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Overlay Init